

# Anne Luise Haulund Vollesen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5371884/publications.pdf>

Version: 2024-02-01

231  
papers

11,941  
citations

36691

53  
h-index

40945

97  
g-index

236  
all docs

236  
docs citations

236  
times ranked

4723  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Cerebral Perfusion, Oxygen Consumption, and Lactate Production in Response to Hypoxic Exposure. <i>Cerebral Cortex</i> , 2022, 32, 1295-1306.	1.6	8
2	PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. <i>Cephalalgia</i> , 2022, 42, 687-695.	1.8	8
3	Arterial responses to infusion of Glucagon-like Peptide-1 in humans: A randomized trial study. <i>Peptides</i> , 2022, 150, 170736.	1.2	0
4	Migraine and light: A narrative review. <i>Headache</i> , 2022, 62, 4-10.	1.8	13
5	Migraine. <i>Nature Reviews Disease Primers</i> , 2022, 8, 2.	18.1	154
6	Brain barriers and their potential role in migraine pathophysiology. <i>Journal of Headache and Pain</i> , 2022, 23, 16.	2.5	17
7	Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura. <i>JAMA Neurology</i> , 2022, 79, 159.	4.5	19
8	Prevalence of neck pain in migraine: A systematic review and meta-analysis. <i>Cephalalgia</i> , 2022, 42, 663-673.	1.8	36
9	Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies. <i>Cephalalgia</i> , 2022, 42, 781-792.	1.8	4
10	Effect of K <sup>ATP</sup> channel blocker glibenclamide on PACAP38-induced headache and hemodynamic. <i>Cephalalgia</i> , 2022, 42, 846-858.	1.8	13
11	Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies. <i>Journal of Headache and Pain</i> , 2022, 23, 43.	2.5	14
12	Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review. <i>Headache</i> , 2022, 62, 453-472.	1.8	9
13	Barriers and gaps in headache education: a national cross-sectional survey of neurology residents in Denmark. <i>BMC Medical Education</i> , 2022, 22, 233.	1.0	11
14	Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study. <i>Frontiers in Neurology</i> , 2022, 13, 871176.	1.1	6
15	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE <sup>2</sup> for research in migraine prevention. <i>Headache</i> , 2022, 62, 690-699.	1.8	6
16	Psychiatric Sequelae Following Whiplash Injury: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2022, 13, 814079.	1.3	3
17	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 <sup>st</sup> edition. <i>Cephalalgia</i> , 2022, 42, 1099-1115.	1.8	5
18	Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. <i>Headache</i> , 2022, 62, 624-633.	1.8	4

#	ARTICLE	IF	CITATIONS
19	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. <i>Journal of Headache and Pain</i> , 2022, 23, .	2.5	143
20	One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey. <i>Journal of Headache and Pain</i> , 2022, 23, .	2.5	7
21	Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 604-616.	2.4	18
22	Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1328-1337.	2.4	14
23	Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers. <i>Cephalalgia</i> , 2021, 41, 99-111.	1.8	14
24	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. <i>Cephalalgia</i> , 2021, 41, 6-16.	1.8	25
25	A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. <i>Cephalalgia</i> , 2021, 41, 33-44.	1.8	65
26	Hypersensitivity to calcitonin gene-related peptide in chronic migraine. <i>Cephalalgia</i> , 2021, 41, 701-710.	1.8	20
27	Intradural artery dilation during experimentally induced migraine attacks. <i>Pain</i> , 2021, 162, 176-183.	2.0	12
28	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. <i>Cephalalgia</i> , 2021, 41, 279-293.	1.8	24
29	Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. <i>European Journal of Neurology</i> , 2021, 28, 1716-1725.	1.7	112
30	Human Models. <i>Headache</i> , 2021, , 55-68.	0.2	4
31	Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. <i>Cephalalgia</i> , 2021, 41, 731-748.	1.8	19
32	Subtype-Specific Off-Label Treatment of Rosacea. <i>Case Reports in Dermatology</i> , 2021, 13, 121-128.	0.3	4
33	Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. <i>Cephalalgia</i> , 2021, 41, 294-304.	1.8	34
34	Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. <i>Pain</i> , 2021, 162, 2512-2520.	2.0	35
35	Opening of ATP sensitive potassium channels causes migraine attacks with aura. <i>Brain</i> , 2021, 144, 2322-2332.	3.7	48
36	Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00741.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Migraine: epidemiology and systems of care. <i>Lancet, The</i> , 2021, 397, 1485-1495.	6.3	310
38	Migraine: integrated approaches to clinical management and emerging treatments. <i>Lancet, The</i> , 2021, 397, 1505-1518.	6.3	139
39	Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients. <i>Annals of Neurology</i> , 2021, 89, 1157-1171.	2.8	58
40	Migraine: disease characterisation, biomarkers, and precision medicine. <i>Lancet, The</i> , 2021, 397, 1496-1504.	6.3	141
41	Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine. <i>Neurology</i> , 2021, 96, e2488-e2499.	1.5	29
42	Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020. <i>Journal of Headache and Pain</i> , 2021, 22, 22.	2.5	25
43	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. <i>Cephalalgia</i> , 2021, 41, 1135-1151.	1.8	19
44	Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study. <i>Cephalalgia</i> , 2021, 41, 1262-1267.	1.8	3
45	Diagnosis and management of migraine in ten steps. <i>Nature Reviews Neurology</i> , 2021, 17, 501-514.	4.9	194
46	Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine. <i>Headache</i> , 2021, 61, 916-926.	1.8	2
47	The Effect of KATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers. <i>Frontiers in Physiology</i> , 2021, 12, 652136.	1.3	14
48	Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment. <i>Lancet Neurology, The</i> , 2021, 20, 460-469.	4.9	56
49	Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. <i>Journal of Headache and Pain</i> , 2021, 22, 78.	2.5	32
50	The chronobiology of migraine: a systematic review. <i>Journal of Headache and Pain</i> , 2021, 22, 76.	2.5	14
51	Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. <i>Journal of Headache and Pain</i> , 2021, 22, 68.	2.5	23
52	Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1687-1698.	0.3	11
53	Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. <i>Journal of Headache and Pain</i> , 2021, 22, 81.	2.5	11
54	Board Walk – August 2021. <i>Cephalalgia</i> , 2021, 41, 1033-1034.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity. <i>Headache</i> , 2021, 61, 1180-1193.	1.8	8
56	Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches. <i>JAMA Network Open</i> , 2021, 4, e2118543.	2.8	38
57	Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study. <i>Journal of Headache and Pain</i> , 2021, 22, 98.	2.5	11
58	Timing and durability of response to erenumab in patients with chronic migraine. <i>Headache</i> , 2021, 61, 1255-1263.	1.8	9
59	Interictal pontine metabolism in migraine without aura patients: A 3 Tesla proton magnetic resonance spectroscopy study. <i>NeuroImage: Clinical</i> , 2021, 32, 102824.	1.4	7
60	PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. <i>Pain Management</i> , 2021, 11, 647-654.	0.7	12
61	Updates in the Diagnostic Approach of Headache. <i>Current Pain and Headache Reports</i> , 2021, 25, 80.	1.3	9
62	PACAP27 induces migraine-like attacks in migraine patients. <i>Cephalalgia</i> , 2020, 40, 57-67.	1.8	57
63	Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1685-1694.	2.4	21
64	Ictal neck pain investigated in the interictal state – a search for the origin of pain. <i>Cephalalgia</i> , 2020, 40, 614-624.	1.8	23
65	Feasibility of Glutamate and GABA Detection in Pons and Thalamus at 3T and 7T by Proton Magnetic Resonance Spectroscopy. <i>Frontiers in Neuroscience</i> , 2020, 14, 559314.	1.4	17
66	Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study. <i>Journal of Headache and Pain</i> , 2020, 21, 134.	2.5	17
67	Latest Insights into the Pathophysiology of Migraine: the ATP-Sensitive Potassium Channels. <i>Current Pain and Headache Reports</i> , 2020, 24, 77.	1.3	18
68	Migraine with aura in women is not associated with structural thalamic abnormalities. <i>NeuroImage: Clinical</i> , 2020, 28, 102361.	1.4	10
69	<p>Reducing Episodic Cluster Headaches: Focus on Galcanezumab</p>. <i>Journal of Pain Research</i> , 2020, Volume 13, 1591-1599.	0.8	2
70	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020, 40, 1026-1044.	1.8	105
71	Googling migraine: A study of Google as an information resource of migraine management. <i>Cephalalgia</i> , 2020, 40, 1633-1644.	1.8	8
72	The migraine landscape on YouTube: A review of YouTube as a source of information on migraine. <i>Cephalalgia</i> , 2020, 40, 1363-1369.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury. <i>Cephalalgia</i> , 2020, 40, 1276-1282.	1.8	17
74	Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache. <i>Annals of Neurology</i> , 2020, 88, 1220-1228.	2.8	35
75	The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. <i>Cephalalgia</i> , 2020, 40, 1474-1488.	1.8	14
76	Opening of BK <sub>Ca</sub> channels alters cerebral hemodynamic and causes headache in healthy volunteers. <i>Cephalalgia</i> , 2020, 40, 1145-1154.	1.8	22
77	Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO). <i>BMJ Open</i> , 2020, 10, e039445.	0.8	5
78	Effect of K <sub>ATP</sub> channel blocker glibenclamide on levromakalim-induced headache. <i>Cephalalgia</i> , 2020, 40, 1045-1054.	1.8	17
79	Intravascular Endothelin-1 does not trigger or increase susceptibility to Spreading Depolarizations. <i>Journal of Headache and Pain</i> , 2020, 21, 127.	2.5	2
80	Migraine. <i>New England Journal of Medicine</i> , 2020, 383, 1866-1876.	13.9	376
81	Neck pain and headache after whiplash injury: a systematic review and meta-analysis. <i>Pain</i> , 2020, 161, 880-888.	2.0	22
82	Post-Traumatic Stress Disorder After Traumatic Brain Injury—A Systematic Review and Meta-Analysis. <i>Neurological Sciences</i> , 2020, 41, 2737-2746.	0.9	29
83	The Stereotypical Image of a Person With Migraine According to Mass Media. <i>Headache</i> , 2020, 60, 1465-1471.	1.8	18
84	Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?. <i>Headache</i> , 2020, 60, 1056-1065.	1.8	58
85	Volume of the rectus capitis posterior minor muscle in migraine patients: a cross-sectional structural MRI study. <i>Journal of Headache and Pain</i> , 2020, 21, 57.	2.5	7
86	Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. <i>Journal of Headache and Pain</i> , 2020, 21, 62.	2.5	50
87	S100B and NSE in Cluster Headache—Evidence for Glial Cell Activation?. <i>Headache</i> , 2020, 60, 1569-1580.	1.8	4
88	Post-traumatic stress disorder attributed to traumatic brain injury in children—a systematic review. <i>Brain Injury</i> , 2020, 34, 857-863.	0.6	4
89	Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. <i>Cephalalgia</i> , 2020, 40, 543-553.	1.8	74
90	Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. <i>Journal of Headache and Pain</i> , 2020, 21, 19.	2.5	12

#	ARTICLE	IF	CITATIONS
91	Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. <i>Cephalalgia</i> , 2020, 40, 1212-1223.	1.8	30
92	Mechanistic Investigations Support Liver Safety of Ubrogapant. <i>Toxicological Sciences</i> , 2020, 177, 84-93.	1.4	13
93	Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura. <i>Headache</i> , 2020, 60, 655-664.	1.8	12
94	Targeting BKCa Channels in Migraine: Rationale and Perspectives. <i>CNS Drugs</i> , 2020, 34, 325-335.	2.7	18
95	Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). <i>Cephalalgia</i> , 2020, 40, 241-254.	1.8	230
96	Persistent post-traumatic headache attributed to mild traumatic brain injury: Deep phenotyping and treatment patterns. <i>Cephalalgia</i> , 2020, 40, 554-564.	1.8	67
97	Reply: Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology. <i>Brain</i> , 2020, 143, e14-e14.	3.7	2
98	Risk Factors for the Development of Post-Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review. <i>Headache</i> , 2020, 60, 1066-1075.	1.8	20
99	Low frequency activation of the sphenopalatine ganglion does not induce migraine-like attacks in migraine patients. <i>Cephalalgia</i> , 2020, 40, 966-977.	1.8	3
100	Increased neck muscle stiffness in migraine patients with ictal neck pain: A shear wave elastography study. <i>Cephalalgia</i> , 2020, 40, 565-574.	1.8	18
101	Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura. <i>Headache</i> , 2020, 60, 724-734.	1.8	16
102	Current understanding of thalamic structure and function in migraine. <i>Cephalalgia</i> , 2019, 39, 1675-1682.	1.8	70
103	Migraine is associated with high brain 5-HT levels as indexed by 5-HT <sub>4</sub> receptor binding. <i>Cephalalgia</i> , 2019, 39, 526-532.	1.8	12
104	Sildenafil and calcitonin gene-related peptide dilate intradural arteries: A 3T MR angiography study in healthy volunteers. <i>Cephalalgia</i> , 2019, 39, 264-273.	1.8	11
105	Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. <i>Lancet</i> , The, 2019, 394, 1030-1040.	6.3	269
106	Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. <i>Brain</i> , 2019, 142, 2644-2654.	3.7	94
107	Board Walk "October 2019. <i>Cephalalgia</i> , 2019, 39, 1470-1471.	1.8	0
108	Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil. <i>Cephalalgia</i> , 2019, 39, 1776-1788.	1.8	18

#	ARTICLE	IF	CITATIONS
109	Extracranial activation of ATP-sensitive potassium channels induces vasodilation without nociceptive effects. <i>Cephalalgia</i> , 2019, 39, 1789-1797.	1.8	18
110	Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. <i>Cephalalgia</i> , 2019, 39, 1798-1808.	1.8	50
111	Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-blind Placebo-controlled Phase 3 Clinical Studies. <i>Headache</i> , 2019, 59, 1788-1801.	1.8	31
112	Levcromakalim, an Adenosine Triphosphate-sensitive Potassium Channel Opener, Dilates Extracerebral but not Cerebral Arteries. <i>Headache</i> , 2019, 59, 1468-1480.	1.8	36
113	Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. <i>Journal of Headache and Pain</i> , 2019, 20, 98.	2.5	64
114	Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study. <i>Peptides</i> , 2019, 121, 170134.	1.2	18
115	Calcitonin gene-related peptide "beyond migraine prophylaxis. <i>Nature Reviews Neurology</i> , 2019, 15, 562-564.	4.9	2
116	Post-traumatic headache: epidemiology and pathophysiological insights. <i>Nature Reviews Neurology</i> , 2019, 15, 607-617.	4.9	131
117	Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT <sub>1B</sub> Receptor Binding. <i>JAMA Neurology</i> , 2019, 76, 834.	4.5	27
118	Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). <i>Journal of Headache and Pain</i> , 2019, 20, 60.	2.5	24
119	Migraine and the trigeminovascular system "40 years and counting. <i>Lancet Neurology</i> , The, 2019, 18, 795-804.	4.9	294
120	Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. <i>Cephalalgia</i> , 2019, 39, 1455-1464.	1.8	79
121	Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. <i>Cephalalgia</i> , 2019, 39, 1407-1420.	1.8	22
122	Ultra-high field MR angiography in human migraine models: a 3.0T/7.0T comparison study. <i>Journal of Headache and Pain</i> , 2019, 20, 48.	2.5	5
123	The changing faces of migraine. <i>Journal of Headache and Pain</i> , 2019, 20, 52.	2.5	1
124	Erenumab in chronic migraine with medication overuse. <i>Neurology</i> , 2019, 92, e2309-e2320.	1.5	163
125	Therapeutic novelties in migraine: new drugs, new hope?. <i>Journal of Headache and Pain</i> , 2019, 20, 37.	2.5	91
126	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2019, 39, 1058-1066.	1.8	4



#	ARTICLE	IF	CITATIONS
127	Calcitonin gene-related peptide and disease activity in cluster headache. <i>Cephalalgia</i> , 2019, 39, 575-584.	1.8	44
128	Neurovascular origin of primary headaches. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 571-572.	2.4	1
129	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. <i>Cephalalgia</i> , 2019, 39, 687-710.	1.8	154
130	The vascular effect of glibenclamide: A systematic review. <i>Cephalalgia Reports</i> , 2019, 2, 251581631988493.	0.2	6
131	Effect of the H <sub>1</sub> -antihistamine clemastine on PACAP38 induced migraine. <i>Cephalalgia</i> , 2019, 39, 597-607.	1.8	19
132	Meningeal contribution to migraine pain: a magnetic resonance angiography study. <i>Brain</i> , 2019, 142, 93-102.	3.7	74
133	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <i>Journal of Headache and Pain</i> , 2019, 20, 6.	2.5	260
134	High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. <i>Peptides</i> , 2019, 112, 43-47.	1.2	6
135	Cortical abnormalities in episodic migraine: A multi-center 3T MRI study. <i>Cephalalgia</i> , 2019, 39, 665-673.	1.8	60
136	The most important advances in headache research in 2018. <i>Lancet Neurology</i> , The, 2019, 18, 5-6.	4.9	9
137	Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 680-689.	2.4	24
138	CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. <i>Cephalalgia</i> , 2019, 39, 374-389.	1.8	58
139	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832.	1.8	245
140	ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. <i>Cephalalgia</i> , 2018, 38, 1026-1037.	1.8	416
141	Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. <i>Neurotherapeutics</i> , 2018, 15, 371-376.	2.1	40
142	High brain serotonin levels in migraine between attacks: A 5-HT <sub>4</sub> receptor binding PET study. <i>NeuroImage: Clinical</i> , 2018, 18, 97-102.	1.4	26
143	Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. <i>Journal of Headache and Pain</i> , 2018, 19, 11.	2.5	11
144	Migraine with visual aura associated with thicker visual cortex. <i>Brain</i> , 2018, 141, 776-785.	3.7	52

#	ARTICLE	IF	CITATIONS
145	The Role of Endothelin in the Pathophysiology of Migraine—a Systematic Review. <i>Current Pain and Headache Reports</i> , 2018, 22, 27.	1.3	32
146	Carbon monoxide inhalation induces headache but no migraine in patients with migraine without aura. <i>Cephalalgia</i> , 2018, 38, 1940-1949.	1.8	5
147	CGRP in human models of primary headaches. <i>Cephalalgia</i> , 2018, 38, 353-360.	1.8	26
148	Carbon monoxide inhalation induces headache in a human headache model. <i>Cephalalgia</i> , 2018, 38, 697-706.	1.8	9
149	Low 5-HT <sub>1B</sub> receptor binding in the migraine brain: A PET study. <i>Cephalalgia</i> , 2018, 38, 519-527.	1.8	26
150	Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. <i>Cephalalgia</i> , 2018, 38, 892-903.	1.8	15
151	Cranial parasympathetic activation induces autonomic symptoms but no cluster headache attacks. <i>Cephalalgia</i> , 2018, 38, 1418-1428.	1.8	32
152	Altered thalamic connectivity during spontaneous attacks of migraine without aura: A resting-state fMRI study. <i>Cephalalgia</i> , 2018, 38, 1237-1244.	1.8	71
153	The relationship between migraine and rosacea: Systematic review and meta-analysis. <i>Cephalalgia</i> , 2018, 38, 1387-1398.	1.8	24
154	Vasomotor reactions in the face and head of patients with migraine. <i>Cephalalgia Reports</i> , 2018, 1, 251581631879054.	0.2	2
155	Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. <i>Journal of Headache and Pain</i> , 2018, 19, 105.	2.5	43
156	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2018, 19, 91.	2.5	97
157	Migraine and cluster headache—the common link. <i>Journal of Headache and Pain</i> , 2018, 19, 89.	2.5	44
158	Early onset of efficacy with erenumab in patients with episodic and chronic migraine. <i>Journal of Headache and Pain</i> , 2018, 19, 92.	2.5	78
159	Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0T. <i>Journal of Headache and Pain</i> , 2018, 19, 44.	2.5	14
160	Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks. <i>JAMA Neurology</i> , 2018, 75, 1187.	4.5	106
161	Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> , 2018, 38, 1611-1621.	1.8	104
162	Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?. <i>Journal of Headache and Pain</i> , 2018, 19, 33.	2.5	5

#	ARTICLE	IF	CITATIONS
163	CGRP in Human Models of Migraine. Handbook of Experimental Pharmacology, 2018, 255, 109-120.	0.9	34
164	Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura. Cephalalgia, 2017, 37, 74-88.	1.8	23
165	Challenges in developing drugs for primary headaches. Progress in Neurobiology, 2017, 152, 70-88.	2.8	25
166	PACAP38 dose-response pilot study in migraine patients. Cephalalgia, 2017, 37, 391-395.	1.8	17
167	Hypoxic mechanisms in primary headaches. Cephalalgia, 2017, 37, 372-384.	1.8	18
168	Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 114-124.	1.8	25
169	Serotonergic mechanisms in the migraine brain – a systematic review. Cephalalgia, 2017, 37, 251-264.	1.8	68
170	Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 125-135.	1.8	31
171	Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia, 2017, 37, 136-147.	1.8	46
172	Increased intrinsic brain connectivity between pons and somatosensory cortex during attacks of migraine with aura. Human Brain Mapping, 2017, 38, 2635-2642.	1.9	59
173	PACAP38: Emerging Drug Target in Migraine and Cluster Headache. Headache, 2017, 57, 56-63.	1.8	19
174	Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain, 2017, 140, 1633-1642.	3.7	105
175	Measurement of Blood Flow Velocity in the Middle Cerebral Artery During Spontaneous Migraine Attacks: A Systematic Review. Headache, 2017, 57, 852-861.	1.8	21
176	Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 425-434.	4.9	589
177	Lifelong contribution to headache science: A tribute to Professor Jes Olesen. Cephalalgia, 2017, 37, 7-7.	1.8	0
178	Calcitonin gene-related peptide and pain: a systematic review. Journal of Headache and Pain, 2017, 18, 34.	2.5	161
179	Triptans and CGRP blockade – impact on the cranial vasculature. Journal of Headache and Pain, 2017, 18, 103.	2.5	50
180	Human models of migraine – short-term pain for long-term gain. Nature Reviews Neurology, 2017, 13, 713-724.	4.9	165

#	ARTICLE	IF	CITATIONS
181	Erenumab (AMG 334) in episodic migraine. <i>Neurology</i> , 2017, 89, 1237-1243.	1.5	120
182	A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.63-e1.	0.9	9
183	Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses. <i>Annals of Neurology</i> , 2017, 82, 925-939.	2.8	41
184	Endovascular thrombectomy and post-procedural headache. <i>Journal of Headache and Pain</i> , 2017, 18, 10.	2.5	6
185	Prevalence and risk of migraine in patients with rosacea: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 454-458.	0.6	36
186	The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine. <i>Journal of Headache and Pain</i> , 2017, 18, 90.	2.5	42
187	PACAP38 in human models of primary headaches. <i>Journal of Headache and Pain</i> , 2017, 18, 110.	2.5	24
188	Sensory migraine aura is not associated with structural grey matter abnormalities. <i>NeuroImage: Clinical</i> , 2016, 11, 322-327.	1.4	42
189	Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. <i>Brain</i> , 2016, 139, 2015-2023.	3.7	74
190	Post procedure headache in patients treated for neurovascular arteriovenous malformations and aneurysms using endovascular therapy. <i>Journal of Headache and Pain</i> , 2016, 17, 73.	2.5	12
191	Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. <i>Pain</i> , 2016, 157, 2773-2781.	2.0	90
192	Migraine induced by hypoxia: an MRI spectroscopy and angiography study. <i>Brain</i> , 2016, 139, 723-737.	3.7	97
193	Change in brain network connectivity during PACAP38-induced migraine attacks. <i>Neurology</i> , 2016, 86, 180-187.	1.5	86
194	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 382-390.	4.9	312
195	Ultrasound tagged near infrared spectroscopy does not detect hyperventilation-induced reduction in cerebral blood flow. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 82-87.	0.6	5
196	Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteers. <i>Cephalalgia</i> , 2016, 36, 172-178.	1.8	14
197	Calcitonin Gene-Related Peptide Modulates Heat Nociception in the Human Brain - An fMRI Study in Healthy Volunteers. <i>PLoS ONE</i> , 2016, 11, e0150334.	1.1	29
198	Effect of motion artifacts and their correction on near-infrared spectroscopy oscillation data: a study in healthy subjects and stroke patients. <i>Journal of Biomedical Optics</i> , 2015, 20, 056011.	1.4	15

#	ARTICLE	IF	CITATIONS
199	Evidence of a Christmas spirit network in the brain: functional MRI study. <i>BMJ, The</i> , 2015, 351, h6266.	3.0	7
200	Structural gray matter abnormalities in migraine relate to headache lateralization, but not aura. <i>Cephalalgia</i> , 2015, 35, 3-9.	1.8	30
201	The temporal evolution of a facial pain syndrome associated with neurovascular contact: a case report. <i>Journal of Headache and Pain</i> , 2015, 16, 12.	2.5	1
202	Can nitric oxide induce migraine in normal individuals?. <i>Cephalalgia</i> , 2015, 35, 1125-1129.	1.8	11
203	Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 Tesla. <i>Journal of Neuroscience</i> , 2015, 35, 13800-13806.	1.7	62
204	Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. <i>Peptides</i> , 2015, 74, 33-42.	1.2	11
205	Cerebral Asymmetry of fMRI-BOLD Responses to Visual Stimulation. <i>PLoS ONE</i> , 2015, 10, e0126477.	1.1	23
206	Research update for articles published in <i>EJCI</i> in 2012. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1010-1023.	1.7	1
207	Carbon monoxide may be an important molecule in migraine and other headaches. <i>Cephalalgia</i> , 2014, 34, 1169-1180.	1.8	19
208	Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta. <i>Cephalalgia</i> , 2014, 34, 712-716.	1.8	15
209	Measurement precision and biological variation of cranial arteries using automated analysis of 3 T magnetic resonance angiography. <i>Journal of Headache and Pain</i> , 2014, 15, 25.	2.5	19
210	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology, The</i> , 2014, 13, 1100-1107.	4.9	333
211	Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. <i>Brain</i> , 2014, 137, 779-794.	3.7	196
212	Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. <i>Brain</i> , 2014, 137, 2951-2959.	3.7	88
213	Natriuretic peptides and cerebral hemodynamics. <i>Regulatory Peptides</i> , 2014, 192-193, 15-23.	1.9	9
214	Calcitonin gene-related peptide and migraine with aura: A systematic review. <i>Cephalalgia</i> , 2014, 34, 695-707.	1.8	26
215	Migraine without aura is not associated with incomplete circle of Willis: a case-control study using high-resolution magnetic resonance angiography. <i>Journal of Headache and Pain</i> , 2014, 15, 27.	2.5	6
216	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan. <i>Scandinavian Journal of Pain</i> , 2013, 4, 211-216.	0.5	6

#	ARTICLE	IF	CITATIONS
217	Intracranial and extracranial arteries in migraine – Authors' reply. <i>Lancet Neurology</i> , The, 2013, 12, 848-849.	4.9	1
218	Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience. <i>Cephalalgia</i> , 2013, 33, 540-553.	1.8	83
219	Provocation of migraine with aura using natural trigger factors. <i>Neurology</i> , 2013, 80, 428-431.	1.5	107
220	Altered Low Frequency Oscillations of Cortical Vessels in Patients with Cerebrovascular Occlusive Disease – A NIRS Study. <i>Frontiers in Neurology</i> , 2013, 4, 204.	1.1	11
221	Vascular changes have a primary role in migraine. <i>Cephalalgia</i> , 2012, 32, 428-430.	1.8	19
222	Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. <i>Cephalalgia</i> , 2012, 32, 140-149.	1.8	111
223	Migraine neurobiology and treatment. <i>Scandinavian Journal of Pain</i> , 2012, 3, 176-176.	0.5	0
224	Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. <i>Cephalalgia</i> , 2011, 31, 683-690.	1.8	29
225	Trigger factors for familial hemiplegic migraine. <i>Cephalalgia</i> , 2011, 31, 1274-1281.	1.8	36
226	Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. <i>Cephalalgia</i> , 2010, 30, 1179-1186.	1.8	365
227	Pharmacological migraine provocation: a human model of migraine. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 773-779.	1.0	2
228	PACAP38 induces migraine-like attacks in patients with migraine without aura. <i>Brain</i> , 2009, 132, 16-25.	3.7	360
229	Pathophysiology of Tension-Type Headache: Potential Drug Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2007, 6, 238-239.	0.8	9
230	No release of interstitial glutamate in experimental human model of muscle pain. <i>European Journal of Pain</i> , 2005, 9, 337-337.	1.4	13
231	Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 395-399.	0.9	29